A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Study of Drug vs. Placebo in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC)
Sponsor: ECOG- ACRIN
Enrolling: Male and Female Patients
IRB Number: AAAO9704
U.S. Govt. ID: NCT02201992
Contact: Naiyer Rizvi MD: 212-305-8610 / nar2144@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if the study drug is safe and evaluate whether adjuvant therapy with the study drug will improve overall survival. The study drug is crizotinib (also known as XALKORI). The study will also collect tumor tissue and blood samples for future research.
This study is closed
Investigator
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with non-small cell lung cancer? Yes No
Have you undergone complete surgical resection for cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Naiyer Rizvi MD
nar2144@cumc.columbia.edu
212-305-8610
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE